Interim PET-directed ongoing studies in early-stage HL
| Reference . | Phase . | Sample . | Stage . | End point . | Pre-iPET CHT . | iPET− arm(s) . | iPET+ arm . | Group/title/NCT no. . | End year . |
|---|---|---|---|---|---|---|---|---|---|
| 41 | II | 660 | IA-IIAf | 5-y EFS | ABVD × 2 | INRT | ABVD × 2 ± INRTPET4− | RHC/NA | 2016 |
| IA-IIAuf | ABVD × 2 | ABVD × 2+INRT − | ABVD × 2 ± ABVD × 2 + INRTPET4 | 00392314 | |||||
| 42 | III | 1797 | IA-IIBf | PFS | ABVD × 2 | ABVD × 1 | escBEACOPP × 2 | EORTC-GELA/H10 | 2011 |
| IA-IIBuf | ABVD × 2 | escBEACOPP × 2 | 00433433 | ||||||
| 43 | II | 123 | IA-IIB blk | 3-y PFS | ABVD × 2 | ABVD × 4 | escBEACOPP × 4 | CALGB/50 801 | 2015 |
| + IFRT | 01118026 | ||||||||
| 44 | II | 200 | IA-IIB blk | 3-y PFS | ABVD × 2 | ABVD × 4 + INRT | escBEACOPP × 4* | ECOG/2410 | 2016 |
| + INRT | 01390584 | ||||||||
| 45 | II | 149 | IA-IIB n-blk | 3-y PFS | ABVD × 2 | ABVD × 2 | escBEACOPP × 2 | CALGB/50 604 | 2013 |
| + IFRT | 01132807 | ||||||||
| 46 | III | 575 | IA-IIA n-blk | PFS | ABVD × 3 | IFRT or | ABVD × 1 + IFRT | NHSFT/RAPID | 2012 |
| No therapy | 00943423 | ||||||||
| 47 | III | 1100 | I-IIAf | 5-y PFS | ABVD × 2 | No therapy | ABVD × 2 + IFRT | GHSG/HD16 | 2013 |
| 00736320 | |||||||||
| 48 | III | 1100 | I-IIrf | 3-y PFS | escBEACOPP × 2 + ABVD × 2 + IFRT | No therapy | escBEACOPP × 2 + ABVD × 2 | GHSG/ HD17 | 2013 |
| 01356680 |
| Reference . | Phase . | Sample . | Stage . | End point . | Pre-iPET CHT . | iPET− arm(s) . | iPET+ arm . | Group/title/NCT no. . | End year . |
|---|---|---|---|---|---|---|---|---|---|
| 41 | II | 660 | IA-IIAf | 5-y EFS | ABVD × 2 | INRT | ABVD × 2 ± INRTPET4− | RHC/NA | 2016 |
| IA-IIAuf | ABVD × 2 | ABVD × 2+INRT − | ABVD × 2 ± ABVD × 2 + INRTPET4 | 00392314 | |||||
| 42 | III | 1797 | IA-IIBf | PFS | ABVD × 2 | ABVD × 1 | escBEACOPP × 2 | EORTC-GELA/H10 | 2011 |
| IA-IIBuf | ABVD × 2 | escBEACOPP × 2 | 00433433 | ||||||
| 43 | II | 123 | IA-IIB blk | 3-y PFS | ABVD × 2 | ABVD × 4 | escBEACOPP × 4 | CALGB/50 801 | 2015 |
| + IFRT | 01118026 | ||||||||
| 44 | II | 200 | IA-IIB blk | 3-y PFS | ABVD × 2 | ABVD × 4 + INRT | escBEACOPP × 4* | ECOG/2410 | 2016 |
| + INRT | 01390584 | ||||||||
| 45 | II | 149 | IA-IIB n-blk | 3-y PFS | ABVD × 2 | ABVD × 2 | escBEACOPP × 2 | CALGB/50 604 | 2013 |
| + IFRT | 01132807 | ||||||||
| 46 | III | 575 | IA-IIA n-blk | PFS | ABVD × 3 | IFRT or | ABVD × 1 + IFRT | NHSFT/RAPID | 2012 |
| No therapy | 00943423 | ||||||||
| 47 | III | 1100 | I-IIAf | 5-y PFS | ABVD × 2 | No therapy | ABVD × 2 + IFRT | GHSG/HD16 | 2013 |
| 00736320 | |||||||||
| 48 | III | 1100 | I-IIrf | 3-y PFS | escBEACOPP × 2 + ABVD × 2 + IFRT | No therapy | escBEACOPP × 2 + ABVD × 2 | GHSG/ HD17 | 2013 |
| 01356680 |
iPET indicates interim PET; CHT, chemotherapy before interim PET imaging; esc, escalated; IPS, international prognostic score; INRT, involved-node radiotherapy; INRTPET4−, INRT is given to only those who have a PET-4 negative result (PET-4 positive arm will be salvaged); n-blk, nonbulky; blk, bulky; NA, not applicable; f, favorable; uf, unfavorable; rf, large mediastinal mass, extranodal involvement, elevated ESR, 3 or more involved nodal areas (stage IIB with risk factor 1 or 2 are not included); Rel/refrac, relapsed or refractory HL; GITIL, Gruppo Italiano Terapie Innovative Nei Linfomi, Italy; GELA-RC, Groupe d'Etude des Lymphomes de l'Adulte-Recherche Clinique, France; ECOG, Eastern Cooperative Oncology Group, United States; SWOG, Southwest Oncology Group, United States; CALGB, Cancer and Leukemia Group B (aka Alliance), United States; RHC, Rambam Health Care Campus, Israel; NCRI, Cancer Research, United Kingdom; NHSFT, NHS Foundation Trust, United Kingdom; GHSG, Deutsche Hodgkin Studiengruppe, Germany; and FIL, Fondazione Italiana Linfomi.
Therapy varies depending on the stage and risk group. Only PET− patients after BEACOPP × 4 will receive INRT; PET+ patients will be off study.